Sarilumab, a monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), has been recommended for PBS listing for patients with rheumatoid arthritis. The Pharmaceutical Benefits Advisory Committee (PBAC) has backed an application by Sanofi-Aventis for sarilumab injection 200 mg (Kevzara) to receive an Authority Required listing for the treatment of patients with severe active RA. At its ...
Already a member?
Enter your email to keep reading.